Richmond Pharmacology is excited to confirm our attendance at AHA Scientific Sessions 2025, hosted by the American Heart Association in New Orleans from 8–10 November.
Representing Richmond at AHA 2025:
Dr Jörg Täubel, Chief Executive Officer
Miquel Serna Pascual, PHD Representative
We look forward to connecting with attendees to discuss Richmond’s expertise in:
Early-phase cardiovascular and cardiometabolic research
First-in-human and dose-ranging studies
Novel biomarkers and digital endpoints
Regulatory engagement and global trial delivery
Patient-first strategies in complex CV trials
If you’re attending AHA 2025 and seeking a clinical development partner with cardiovascular expertise, arrange a meeting with us: info@richmondpharmacology.com
Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology
December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
